What does this research mean for the field?

GLP-1 receptor agonists (GLP-1RAs) are primarily initiated in type 2 diabetes patients after the use of three or more glucose-lowering agents, in line with UK clinical guidelines. Novelty: ClaimNovelty.CONFIRMATORY. Consensus alignment: ConsensusAlignment.SUPPORTS_CONSENSUS.

What question did this study set out to answer?

To analyze treatment patterns before the initiation of GLP-1 receptor agonists in patients with type 2 diabetes in the UK.

synapse

⌘+K

synapse

⌘+K

March 1, 2026

Real-world treatment trajectories preceding GLP-1 receptor agonist initiation in type 2 diabetes: A descriptive UK population-based cohort study on adherence to national clinical guidelines.

Key Points

To analyze treatment patterns before the initiation of GLP-1 receptor agonists in patients with type 2 diabetes in the UK.
Descriptive cohort study design
Population-based data analysis in the UK
Assessment of treatment trajectories prior to GLP-1RA initiation
Most patients initiated GLP-1RAs after using three or more glucose-lowering agents
Post-2018, many received SGLT-2 inhibitors alongside GLP-1RAs
CVD history did not affect prescribing patterns

Abstract

GLP-1RAs were predominantly initiated following ≥3 glucose-lowering agents, consistent with contemporary UK guidance (NG28). Post-2018, most GLP-1RA initiators received SGLT-2is concomitantly. However, CVD history did not influence prescribing patterns, underscoring missed opportunities to optimise the prevention of cardiovascular events and slow the progression of CVD.

Bookmark

Cite This Study

Ulrich et al. (Wed,) studied this question.

synapsesocial.com/papers/69a3d7dfec16d51705d2e416 https://doi.org/https://doi.org/10.1111/dom.70548

Bookmark